The Conversation (0)
Oncolytics Biotech announced Dr. Matt Coffey, their president and CEO will be presenting an update on pelareorep in a clinical case study at the Oncolytic Virotherapy Summit.
Oncolytics Biotech (TSX:ONC; OTCQX:ONCYF) announced Dr. Matt Coffey, their president and CEO will be presenting an update on pelareorep in a clinical case study at the Oncolytic Virotherapy Summit.
As quoted in the press release:
The conference takes place on December 5th, 6th and 7th in Miami, Florida.
“The Oncolytic Virotherapy Summit offers us another opportunity to highlight our extensive experience with pelareorep in the clinic and to illustrate its ability to induce an inflamed tumor phenotype amongst our peers and for potential partners,” said Dr. Coffey. “Our clinical experience with pelareorep has led us to favorable feedback from the FDA following our end-of-phase 2 meeting which helps us define a clear regulatory path in metastatic breast cancer and a single 400-patient phase 3 registration study. Our phase 3 protocol will be made available following evaluation and completion of discussions with clinical advisors, potential partners and the EMA.”
Source: www.newswire.ca